OpenNashEarnings
NVO

Pharmaceuticals · NYSE: NVO

Novo Nordisk earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 2 Feb 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 2026

Wegovy pill, now launched in eight countries, generated DKK 5,394 million in the quarter as Novo prepares a US CagriSema launch in early 2027.

The oral obesity pill was the main change this quarter. Wegovy pill holds around 80% of US new-to-brand prescriptions and is now launched in eight countries. Ozempic pill has replaced Rybelsus in the US, and Medicare's Bridge programme opened obesity coverage from 1 July. Novo says it is treating 5.6 million people with obesity. Both US and International operations returned to growth, led by obesity.

Read the Q3 2026 summary →

Quarters

KPI history

20-F filings